Trading is not only strategy—it is biology. Hormones and neural signals shape risk and execution before logic begins. This article treats biology not as an edge to exploit, but as a risk to manage.
The Biological Edge: Why Your Trading Performance Is Shaped Before You Click “Buy” Read More »
The India–US Interim Trade Deal is a high-resolution trade-off: India exchanges domestic protection for U.S. energy and silicon access. The $500 billion purchase plan could boost manufacturing, but energy crowding-out and tariff dismantling pose risks to SMEs and strategic autonomy.
India-US Interim Trade Deal: The Structural Breakdown Read More »
The Union Budget 2026-27 delivers a stability-first roadmap built on fiscal discipline, capex acceleration, and tech self-reliance through ISM 2.0 and Biopharma SHAKTI. While the macro setup remains structurally bullish, higher STT and MAT changes introduce new friction for active market participants.
Union Budget 2026 – India pays the “Stability” Premium Read More »
High win-rate trading is a cognitive mirage. Markets reward expectancy, not accuracy—yet traders sell winners early and hold losers too long. This piece reframes performance through risk-first math and ergodic systems built to survive probabilities, not chase certainty.
📈Win-Rate Myth: Why a 70% Win-Rate Is Killing Your Trading Account? Read More »
